Soluble MHC class I complexes for targeted immunotherapy

Anna Schappert, Jonathan P Schneck, Lauren Suarez, Mathias Oelke, Christian Schütz

Research output: Contribution to journalReview article

Abstract

Major histocompatibility complexes (MHC) have been used for more than two decades in clinical and pre-clinical approaches of tumor immunotherapy. They have been proven efficient for detecting anti-tumor-specific T cells when utilized as soluble multimers, immobilized on cells or artificial structures such as artificial antigen-presenting cells (aAPC) and have been shown to generate effective anti-tumor responses. In this review we summarize the use of soluble MHC class I complexes in tumor vaccination studies, highlighting the different strategies and their contradicting results. In summary, we believe that soluble MHC class I molecules represent an exciting tool with great potential to impact the understanding and development of immunotherapeutic approaches on many levels from monitoring to treatment.

Original languageEnglish (US)
Pages (from-to)255-258
Number of pages4
JournalLife Sciences
Volume209
DOIs
StatePublished - Sep 15 2018

Fingerprint

Major Histocompatibility Complex
Immunotherapy
Tumors
Neoplasms
Immobilized Cells
T-cells
Antigen-Presenting Cells
Vaccination
T-Lymphocytes
Molecules
Monitoring
Therapeutics

Keywords

  • Immunotherapy
  • MHC-class I
  • T cells
  • Tumor
  • Vaccination

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Soluble MHC class I complexes for targeted immunotherapy. / Schappert, Anna; Schneck, Jonathan P; Suarez, Lauren; Oelke, Mathias; Schütz, Christian.

In: Life Sciences, Vol. 209, 15.09.2018, p. 255-258.

Research output: Contribution to journalReview article

Schappert, A, Schneck, JP, Suarez, L, Oelke, M & Schütz, C 2018, 'Soluble MHC class I complexes for targeted immunotherapy', Life Sciences, vol. 209, pp. 255-258. https://doi.org/10.1016/j.lfs.2018.08.023
Schappert, Anna ; Schneck, Jonathan P ; Suarez, Lauren ; Oelke, Mathias ; Schütz, Christian. / Soluble MHC class I complexes for targeted immunotherapy. In: Life Sciences. 2018 ; Vol. 209. pp. 255-258.
@article{f0831559fcc14ab39dcc800580b376c6,
title = "Soluble MHC class I complexes for targeted immunotherapy",
abstract = "Major histocompatibility complexes (MHC) have been used for more than two decades in clinical and pre-clinical approaches of tumor immunotherapy. They have been proven efficient for detecting anti-tumor-specific T cells when utilized as soluble multimers, immobilized on cells or artificial structures such as artificial antigen-presenting cells (aAPC) and have been shown to generate effective anti-tumor responses. In this review we summarize the use of soluble MHC class I complexes in tumor vaccination studies, highlighting the different strategies and their contradicting results. In summary, we believe that soluble MHC class I molecules represent an exciting tool with great potential to impact the understanding and development of immunotherapeutic approaches on many levels from monitoring to treatment.",
keywords = "Immunotherapy, MHC-class I, T cells, Tumor, Vaccination",
author = "Anna Schappert and Schneck, {Jonathan P} and Lauren Suarez and Mathias Oelke and Christian Sch{\"u}tz",
year = "2018",
month = "9",
day = "15",
doi = "10.1016/j.lfs.2018.08.023",
language = "English (US)",
volume = "209",
pages = "255--258",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Soluble MHC class I complexes for targeted immunotherapy

AU - Schappert, Anna

AU - Schneck, Jonathan P

AU - Suarez, Lauren

AU - Oelke, Mathias

AU - Schütz, Christian

PY - 2018/9/15

Y1 - 2018/9/15

N2 - Major histocompatibility complexes (MHC) have been used for more than two decades in clinical and pre-clinical approaches of tumor immunotherapy. They have been proven efficient for detecting anti-tumor-specific T cells when utilized as soluble multimers, immobilized on cells or artificial structures such as artificial antigen-presenting cells (aAPC) and have been shown to generate effective anti-tumor responses. In this review we summarize the use of soluble MHC class I complexes in tumor vaccination studies, highlighting the different strategies and their contradicting results. In summary, we believe that soluble MHC class I molecules represent an exciting tool with great potential to impact the understanding and development of immunotherapeutic approaches on many levels from monitoring to treatment.

AB - Major histocompatibility complexes (MHC) have been used for more than two decades in clinical and pre-clinical approaches of tumor immunotherapy. They have been proven efficient for detecting anti-tumor-specific T cells when utilized as soluble multimers, immobilized on cells or artificial structures such as artificial antigen-presenting cells (aAPC) and have been shown to generate effective anti-tumor responses. In this review we summarize the use of soluble MHC class I complexes in tumor vaccination studies, highlighting the different strategies and their contradicting results. In summary, we believe that soluble MHC class I molecules represent an exciting tool with great potential to impact the understanding and development of immunotherapeutic approaches on many levels from monitoring to treatment.

KW - Immunotherapy

KW - MHC-class I

KW - T cells

KW - Tumor

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=85051362007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051362007&partnerID=8YFLogxK

U2 - 10.1016/j.lfs.2018.08.023

DO - 10.1016/j.lfs.2018.08.023

M3 - Review article

C2 - 30102903

AN - SCOPUS:85051362007

VL - 209

SP - 255

EP - 258

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

ER -